# A 21-Day Topical Safety Study of Diltiazem Hydrochloride Using a Cumulative Irritant Patch Test Design

> **NCT01821274** · PHASE1 · UNKNOWN · sponsor: **Ventrus Biosciences, Inc** · enrollment: 30 (estimated)

## Conditions studied

- Skin Irritation

## Interventions

- **DRUG:** Diltiazem Hydrochloride 2% Cream
- **DRUG:** Vehicle Cream
- **DRUG:** 0.1% solution o sodium lauryl sulfate (SLS)
- **DRUG:** Saline 0.9%

## Key facts

- **NCT ID:** NCT01821274
- **Lead sponsor:** Ventrus Biosciences, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-03
- **Primary completion:** 2013-07
- **Final completion:** 2013-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2013-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01821274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01821274, "A 21-Day Topical Safety Study of Diltiazem Hydrochloride Using a Cumulative Irritant Patch Test Design". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01821274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*